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bjectives We sought to assess outcomes of alcohol septal ablation (ASA) in high-risk patients.
ackground Because surgical myectomy is the preferred treatment in patients with symptomatic
ypertrophic obstructive cardiomyopathy (HOCM) at our institution, we perform ASA in patients
ho are at high risk for surgery.
ethods We studied 55 symptomatic HOCM patients (mean age 63  13 years, 67% women, mean
ollow-up 8  1 years), at high risk for surgery (as the result of age/comorbidities) who had ASA
etween 1997 and 2000. The following were recorded at baseline, 3 months, and 1 year: septal
hickness, maximal (resting or provocable) left ventricular outﬂow tract gradient, Minnesota living
ith heart failure questionnaire score, and the presence of a permanent pacemaker. All-cause mor-
ality was recorded.
esults: No patients died at 48 h, 2 died at 1 year, 7 died at 5 years, and 13 died at 10 years. Only
ge 65 years at time of ASA predicted long-term mortality (log-rank p  0.03). Mean maximal left
entricular outﬂow tract gradient (104  35 mm Hg vs. 49  28 mm Hg), septal thickness (2.4 
.4 cm vs. 1.8  0.6 cm), and Minnesota living with heart failure score (63 vs. 25) improved at 3
onths, compared with baseline (all p  0.001), with no signiﬁcant changes at 1 year. New perma-
ent pacemaker was present in 26% of patients.
onclusions In symptomatic HOCM patients who are at high risk for surgery, ASA is associated
ith symptomatic improvement and low short-term mortality; with long-term mortality only associ-
ted with older age at time of procedure. In symptomatic HOCM patients at high-risk for surgery,
SA is a viable option. (J Am Coll Cardiol Intv 2008;1:432–8) © 2008 by the American College of
ardiology Foundation
rom the Departments of *Cardiovascular Medicine and †Cardiothoracic Surgery, Heart and Vascular Institute, Cleveland Clinic,
leveland, Ohio.anuscript received January 11, 2008; revised manuscript received April 11, 2008, accepted May 22, 2008.
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433n patients with hypertrophic obstructive cardiomyopathy
HOCM), the presence of dynamic left ventricular outflow
LVOT) obstruction is associated with adverse outcomes (1).
espite maximal medical therapy, such patients frequently
emain intractably symptomatic and often require further
herapy. Although surgical myectomy has excellent long-term
utcomes, it is invasive, and its results are limited to a few
enters with adequate experience (2–6). After the introduction
f percutaneous alcohol septal ablation (ASA) (7), there was a
remendous surge in the number of such procedures being
erformed (8). However, enthusiasm for ASA has been tem-
ered recently as the result of concerns for increased peripro-
edural complications, risk of ventricular tachycardia (VT), and
otential sudden cardiac death (9,10). Although multiple
tudies have demonstrated symptomatic improvement and
xcellent short-term survival, a paucity of data still exists
egarding long-term outcomes after ASA (11–15).
We have achieved excellent long-term outcomes in patients
ho undergo surgical myectomy at our institution (16). There-
ore, it is the preferred treatment in symptomatic HOCM
atients who do not have prohibitive comorbidities. We
ypically perform ASA in symptomatic HOCM patients that
re considered to be at high risk for surgery (as the result of age
r other comorbidities). Primarily, we sought to assess the
hort- and long-term outcomes of percutaneous ASA in such
igh-risk HOCM patients. Secondarily, we compared the
ong-term mortality of patients undergoing ASA to those
ndergoing isolated surgical myectomy.
ethods
atient selection and acquisition of clinical data. Between
997 and 2000, 645 patients were evaluated at our institu-
ion for suspected HOCM. The diagnosis of HOCM was
ased on standard clinical criteria, i.e., history, physical
xamination, electrocardiography, and echocardiography
17,18). Baseline demographic, clinical, medication use, and
lectrocardiographic data were obtained at the time of initial
ffice visit. All patients were taking medications at maxi-
um tolerable dosages. The decision regarding further
reatment (surgery vs. ASA) was based upon the presence of
ymptoms. The Social Security Death Index (SSDI) was
ueried to determine all-cause mortality. We chose to use
ll-cause mortality as our primary end point because it is
ore objective and unbiased than “cardiac mortality” (19).
he cause of death was ascertained if it was available.
lcohol septal ablation group. Of these 645 individuals, 55
ymptomatic patients were deemed to be high-risk surgical
andidates (41% because of age 70 years, 30% because of
evere lung/liver or kidney disease, 11% because of morbid
besity, 11% because of significant autoimmune disease, and
% because of other reasons) by a consensus among the
ardiologists and cardiothoracic surgeons participating in
he care of each patient. Patients with a primary mitral valve croblem were excluded, and higher-risk surgery (myectomy
lus mitral valve surgery) was still preferred in such patients.
hese 55 high-risk patients were referred for ASA. After
nformed consent, these patients were prospectively in-
luded in a registry, approved by the institutional review
oard, established in 1997. The presence of a permanent
acemaker (PPM) at baseline or inserted just before or after
SA in the periprocedural phase) and automatic implant-
ble cardioverter defibrillator (AICD) were recorded. The
resence of VT (sustained or nonsustained), defined as 3 or
ore consecutive ventricular beats at a rate120 beats/min,
as documented (20). All patients undergoing ASA filled
ut a Minnesota Living With Heart Failure (MLWHF)
uestionnaire at baseline and at 3 months’ follow-up (21).
ew York Heart Association (NYHA) functional class was
etermined at baseline and at 3 months’ follow-up. The
eed for repeat ASA and myec-
omy was recorded.
yectomy group. In the same
ime frame (1997 to 2000), 98
atients underwent isolated my-
ctomy (excluding those patients
here myectomy was combined
ith another procedure) (16).
o patients in the myectomy
roup had severe renal, kidney,
r lung disease. A propensity
nalysis that matched patients
ased on age, gender, and base-
ine NYHA functional class was
sed to identify myectomy pa-
ients that formed a control
roup for comparison to those
hat underwent ASA.
chocardiography protocol.
aseline and follow-up echocar-
iographic studies were per-
ormed with commercially avail-
ble instruments at the time (Sequoia, Acuson, Mountview,
alifornia; Phillips, Andover, Massachusetts; and GE, Mil-
aukee, Wisconsin), as part of standard clinical practice.
asal interventricular septal thickness was recorded with a
tandard M-mode echocardiography. Left ventricular
utflow peak velocity was measured by continuous-wave
oppler echocardiography, and LVOT pressure gradient
as estimated with the simplified Bernoulli equation
22). Care was taken to avoid contamination of the
VOT waveform by the mitral regurgitation jet (1). In
atients with resting LVOT gradients 30 mm Hg,
rovocative maneuvers, including Valsalva and amyl ni-
rite, were used. The degree of resting mitral regurgita-
ion was assessed by color Doppler and quantified by flow
Abbreviations
and Acronyms
AICD  automatic
implantable cardioverter
defibrillator
ASA  alcohol septal
ablation
HOCM  hypertrophic
obstructive cardiomyopathy
LVOT  left ventricular
outflow tract
MLWHF  Minnesota Living
With Heart Failure
MR  mitral regurgitation
NYHA  New York Heart
Association
PPM  permanent
pacemaker
SSDI  Social Security
Death Index
VT  ventricular tachycardiaonvergence method (23), on a scale of 0 to 4 (0  none,
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434  mild, 2  moderate, 3  moderately severe, and
  severe).
lcohol septal ablation protocol. All patients that were
andidates for ASA underwent diagnostic catheterization to
valuate for concomitant coronary artery disease, suitability
f a septal perforator branch of the left anterior descending
rtery, appropriate angle of origin, and length of the septal
ranch. Significant epicardial coronary artery disease was
efined as 50% stenosis. At the beginning of the proce-
ure, a temporary pacemaker was placed in the right
entricle. The protocol, under contrast echocardiography
uidance, has been described previously (14).
tatistical analysis. Baseline demographics, risk factors, and
linical variables are descriptively summarized for the group.
ontinuous variables are expressed as mean  standard
eviation. Categorical data are presented as percent fre-
uency. Differences between the groups (ASA vs. myec-
omy) were compared with the use of the Student t test for
ontinuous variables and the chi-square test for categorical
ariables. Paired t-testing was performed to compare differ-
nces between same patients at baseline and during follow-
p. Survival analysis was performed with Cox proportional
azards and relative risk of the individual tested variables
as calculated. Univariate survival analysis is graphically
emonstrated with the use of Kaplan-Meier curves. As
iscussed earlier, we performed propensity matching with
ogistic regression analysis (24). Data assembly and basic
tatistical comparisons were performed with JMP Software
ersion 6.0.2 (SAS Institute, Cary, North Carolina). Ad-
anced statistical analysis was performed with Statistica
ersion 6.1 (Statsoft, Tulsa, Oklahoma). A p value  0.05
Table 1. Baseline Characteristics of Patients Who Underwent Alcohol Sept
Al
Women*
Age, yrs (range)*
History of syncope
History of atrial ﬁbrillation*
History of hypertension
History of coronary artery disease
NYHA functional class 2*
Beta blocker use
Calcium channel blocker use
% patients with left ventricular ejection fraction 55%
Mean resting LVOT gradient (range), mm Hg
Mean provocable LVOT gradient (range)
Resting or provocable LVOT gradient 50 mm Hg
Mean upper interventricular septal thickness, cm
Baseline permanent pacemaker
*p 0.01.
HOCM hypertrophic obstructive cardiomyopathy; LVOT left ventricular outflow tract; NYHAas considered significant. pesults
aseline data for the ASA and myectomy groups. All ASA
atients were symptomatic at baseline (96% had NYHA
unctional class 3) and a significant proportion had evi-
ence of pre-existing conduction abnormalities (5 patients
ad left bundle branch block, 7 had right bundle branch
lock). There were no patients with obstructive left main or
roximal left anterior descending disease. All living patients
eturned at 3 months, with 47 returning at 1 year for
ymptom evaluation and echocardiography. All-cause mor-
ality was ascertained in every patient by SSDI. The mean
ollow-up for outcomes (all cause mortality and repeat
nterventions) was 8  1 years in ASA group and 8  2
ears in myectomy group. The baseline demographics are
hown in Table 1.
utcomes data of both groups. In the ASA group, there
ere no deaths at 48 h, 1 (2%) at 1 month, 2 (4%) at 1 year,
(13%) at 5 years, and 13 (24%) at up to 10 years’
ollow-up. Only age 65 years at time of ASA was
redictive of worse long-term survival (p 0.03, Figs. 1 and
). Table 2 describes the characteristics of ASA patients
ho died during follow-up.
During follow-up, mortality in myectomy group was 8%.
ubsequently, we performed propensity matching of 2
roups, based on age, gender, and baseline NYHA func-
ional class, which resulted in 2 groups of 28 patients each
Table 3). In these groups, on univariate survival analysis,
here was no significant difference in long-term mortality
log-rank p value  0.12).
linical and echocardiographic response after ASA. After
SA, there was a significant reduction in number of
lation and Surgical Myectomy Between 1997 and 2000
Septal Ablation (n  55) Surgical Myectomy (n  98)
37 (67%) 43 (44%)
13 (38–85), median 65 50  14 (15–76), median 51
8 (15%) 28 (29%)
16 (29%) 6 (6%)
5 (9%) 14 (14%)
3 (5%) 12 (12%)
96% 40%
29 (58%) 71 (73%)
21 (43%) 39(40%)
55 (100%) 98 (100%)
70  44 (7–175) 66  44 (10–216)
08  41 (50–220) 107  36 (36–207)
55 (100%) 98 (100%)
2.3  0.5 2.3  0.4
11 (20%) 13 (13%)
York Heart Association.al Ab
cohol
63 
1atients with NYHA functional class3 (96% vs. 17%). All
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435atients had normal ejection fractions at baseline (55%),
ith no change at follow-up. Most patients had an im-
rovement in MLWHF score (98%), maximal LVOT
radients (82%), upper septal thickness (91%), and mitral
egurgitation (MR) (85%) at 3 months versus baseline (Figs.
to 5). The mean MLWHF score (62  22 vs. 24  22),
esting LVOT gradient (31  26 mm Hg vs. 72  46 mm
g), maximal (either resting or provocable) LVOT gradient
49  28 mm Hg vs. 104  35 mm Hg), maximal upper
eptal thickness (1.8  0.6 cm vs. 2.4  0.4 cm), and mean
R (1.4  0.9 vs. 2.2  1.1) improved at 3 months versus
aseline (all p  0.001). Of the 47 patients that had 1-year
ollow-up data available, the resting and maximal LVOT
radients changed minimally (31 39 mm Hg and 51 50
m Hg, all p  NS), compared with 3-month gradients.
here was no further reduction in upper septal thickness at
-year follow-up (1.91  0.47 cm, p  NS). However, the
R at 1-year follow-up was slightly more than at 3 months
2.6  1.8, p  0.01).
ailure of ASA and need for repeat intervention. Nine pa-
ients had persistent or recurrent symptoms and underwent
epeat intervention. Five patients underwent myectomy, 3
nderwent repeat ASA, and 1 had additional mitral valve
urgery at our institution (at up to 10 years’ follow-up). In
his group of 9 patients, the mean age was 64  13 years,
nd 5 patients were women. These patients’ persistent
ymptoms were reflected in the mean 3-month MLWHF
core of 36  21. Furthermore, at 3 months, the mean
pper septal thickness and maximal LVOT gradient were
.1  0.4 cm and 69  33 mm Hg, respectively. After the
epeat procedure, the mean upper septal thickness and
aximal LVOT gradient improved to 2.1  0.4 cm and 13
22 mm Hg, respectively. All patients had NYHA
unctional class 2. Two of these patients died during
Figure 1. Kaplan-Meier Curves Demonstrating Difference in Long-Term
Survival in Alcohol Ablation Group, on the Basis of Age
Patients 65 years of age had worse survival than those younger.ollow-up.omplications after ASA. Permanent pacemakers were im-
lanted in 14 of 55 (25.5%) patients after ASA. Thirteen
atients were PPM dependent at 3-month follow-up be-
ause of underlying complete heart block. Of the 18 patients
hat had Holter monitoring at baseline, none had docu-
ented VT. At 1-year follow-up, 36 had Holter monitor-
ng. Eleven of these patients had nonsustained VT on
olter monitoring, and 3 of these patients had an AICD
laced because of sustained VT. None of the patients had
ICD discharges at 1-year follow-up. There were no
rocedure-related mortalities. One patient had a dissection
f left anterior descending artery, requiring emergent stent-
ng. No alcohol was given, and this patient was excluded
rom analysis.
iscussion
o the best of our knowledge, this study is one of the first to
valuate the long-term outcomes of ASA in symptomatic
OCM patients who were deemed to be at high risk for
urgery and compare them with patients who underwent
urgical myectomy. The immediate hemodynamic and symp-
omatic improvements were maintained up to 1 year after ASA
n a majority of cases. On survival analysis, age 65 years was
he only predictor of long-term outcomes after ASA. Patients
65 years were considered to be at greater risk for surgery
particularly if they had other comorbid conditions) by our
ardiothoracic surgeons. Therefore, this age was used as the
Figure 2. Univariate Survival Analysis of Patients Undergoing
Alcohol Ablation
Only patients who were 65 years of age achieved statistical signiﬁcance
(p  0.05; other: p  0.10). CI  conﬁdence interval; LVOT  left ventricu-
lar outﬂow tract; MR  mitral regurgitation; VT  ventricular tachycardia.
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436utoff for survival analysis. The comorbid condition that
recluded the individual patient from undergoing surgical
yectomy was generally the cause of mortality in patients65
ears that died after ASA (Table 3). A recent study demon-
trated favorable results in 329 HOCM patients at 10 years
fter ASA (15). However, this study’s patient population was
uch healthier than ours, with no significant comorbidities
hat would preclude them from undergoing surgical myectomy.
We further compared the long-term mortality data of
hese patients with a group of propensity-matched symp-
omatic HOCM patients who underwent isolated myec-
omy during the same time frame. There was no difference
n mortality between these 2 groups. Mortality in ASA
roup was comparable with the published long-term myec-
omy outcomes (at least 5 years’ follow-up) at other insti-
utions (1.3% to 3.5% per year) (4,25).
There was also an increased frequency of PPM placement
n patients after ASA, likely related to the older baseline age
f the population. A recent study has demonstrated that
ssessment of intracardiac conduction during ASA can help
Table 2. Description of Alcohol Septal Ablation Patients Who Died During F
Deceased
Patient
Age at Procedure
(yrs)
Reason for Re
1 82 Old age
2 77 Old age
3 83 Old age
4 63 History of mult
5 82 Old age
6 83 Old age
7 78 Old age
8 69 History of recur
9 60 Severe lung dis
10 65 Signiﬁcant psyc
11 71 Old age plus ac
12 66 Cirrhosis of live
13 46 Severe renal fai
Table 3. Characteristics of Propensity-Matched Patients in 2 Groups
Women
Age, yrs (range)
NYHA functional class 2
History of syncope
Beta blocker use
Calcium channel blocker use
Mean resting LVOT gradient, mm Hg
Mean provocable LVOT gradient
Mean upper interventricular septal thickness, cm
Baseline permanent pacemaker
All p 0.10.LVOT left ventricular outflow tract; NYHA New York Heart Association.dentify patients that are likely to develop future complete
eart block after the procedure (26). A major concern with
SA is the theoretic increased risk of VT and sudden
ardiac death (27). Our study reiterates previous findings
hat a significant proportion of these patients have VT (27).
owever, only 3 patients in the ASA group had an
mplantable cardioverter defibrillator implanted, with no
ischarges. The significance of VT is likely diminished in
lder, as compared to younger, HOCM patients.
Furthermore, reintervention may be necessary after ASA.
here are many reasons for a suboptimal result after ASA,
ncluding the degree/location of septal regression following
lcohol injection (28) and multifactorial etiology of LVOT
bstruction, including the presence of mitral apparatus
bnormalities like anterior displacement of the papillary
uscles (29–31) and leaflet elongation (32). Hence, the
ecision regarding ASA versus surgery should likely involve
he following factors: 1) understanding the etiology of
VOT obstruction; 2) institutional experience with surgical
yectomy; and 3) patient specific comorbidities. In patients
-Up
o Alcohol Septal
on
Age at Death
(yrs) Cause of Death
85 Respiratory failure
84 Unknown
84 Unknown
lve surgeries 70 Liver failure
88 Unknown
84 Cardiac arrest
81 Unknown
nous thrombosis 74 Unknown
62 Unknown
problems 71 Pneumonia
olecystitis 78 Unknown
69 Cirrhosis of liver
46 Renal Failure
lcohol Septal Ablation
(n  28)
Surgical Myectomy
(n  28)
12 (43%) 12 (43%)
56 11 56 12
93% 93%
4 (14%) 9 (33%)
15 (55%) 21 (77%)
12 (43%) 12 (43%)
72 43 65 43
108 37 101 38
2.3 0.4 2.1 0.4
9 (32%) 5 (18%)ollow
ferral t
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437ith concomitant mitral valve problems, myectomy plus
itral valve surgery should be considered.
tudy limitations and future outlook. Because this study was
onducted at a large tertiary-care referral center, there is a
istinct possibility of selection bias. Our highly skilled
ardiothoracic surgeons have extensive experience in per-
orming myectomy; hence, the threshold for referring pa-
ients for ASA is very high. Thus, patients undergoing ASA
ere sicker and deemed poor candidates for surgery. One
ight argue that these variables make a comparison of
utcomes between ASA (high-risk group) and myectomy
low-risk group) flawed. Nevertheless, there is no significant
ifference in mortality between the 2 propensity-matched
roups. However, the sample size expectedly becomes very
mall after propensity matching. To fully ascertain superi-
rity/noninferiority of one technique over another, a ran-
omized study is warranted, if deemed ethically feasible.
Figure 3. Change in Minnesota Living With Heart Failure Score at
3 Months, Compared With Baseline
All patients had an improvement in the Minnesota Living With Heart Fail-
ure score at 3 months’ follow-up.
Figure 4. Change in Maximal (Resting or Provocable) LVOT Gradient at
3 Months, Compared With Baseline
Vast majority of the patients had a signiﬁcant reduction in the maximal leftt
ventricular outﬂow tract (LVOT) gradient at 3-month follow-up.Another limitation includes a loss of follow-up with time.
t our tertiary-care center, patients are referred for high-
isk procedures from all over the country, and some of these
atients prefer to follow-up locally. However, in the current
tudy, the lack of follow-up pertains only to symptom/
rrhythmia evaluation and echocardiographic data. Because
e performed a SSDI query, we have an accurate estimate of
ll-cause mortality. Holter monitoring was not available in
ll patients at baseline or during follow-up. Also, short-term
24- to 48-h) arrhythmia monitoring can potentially miss
pisodes of asymptomatic VT. These factors might have
otentially accounted for no documented VT at baseline.
he impact of VT and potential benefit of ICD in such
atients needs to be prospectively studied.
onclusions
n symptomatic HOCM patients who are deemed to be
igh-risk for surgery, ASA is associated with substantial
ymptomatic improvement and low short-term mortality,
ith long-term mortality only associated with older age at
Figure 5. Changes in Basal Interventricular Septal Thickness and Mitral
Regurgitation
(A) Change in basal interventricular septal thickness at 3 months, com-
pared with baseline. (B) Change in mitral regurgitation at 3 months, com-
pared with baseline.he time of procedure. After adjustment of baseline differ-
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438nces, the long-term mortality is not significantly different
hen compared to myectomy. In symptomatic HOCM
atients who are at high-risk for surgery, ASA is a viable
ption.
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